Exact Sciences Provides Update on Strong Launch Trajectory of Cologuard®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
- Dollar Tree climbs after Jefferies upgrades stock on improving traffic
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
UPDATE: Mizuho Securities Raises Price Target Following Exact Sciences (EXAS) Positive Test Volume Preannouncement
June 26, 2015 7:51 AM EDT(Updated - June 26, 2015 7:54 AM EDT)
Mizuho Securities reiterates a Buy rating on Exact Sciences (NASDAQ: EXAS), and raised the price target to $35.00 (from $30.00), following positive test volume preannouncement. EXAS reported 21,000 Cologuard tests completed, vs prior estimates of 18,000.
Analyst Peter Lawson... More
Exact Sciences (EXAS) to End Q2 with 21K Completed Cologuard Tests
June 25, 2015 6:39 AM EDTExact Sciences Corp. (Nasdaq: EXAS) today announced that it expects to end the second quarter of 2015 with approximately 21,000 completed Cologuard tests.
More than 13,800 physicians ordered at least one Cologuard test since the October 2014 launch and the patient compliance rate for Cologuard rose to 73 percent.
The company... More
